Latest Epidermal growth factor receptor Stories
Scientists believe they may have found a new target for treating triple negative breast cancer â€“ one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.
Lung cancer, the most common cause of cancer-related death in men and women, is responsible for 1.3 million deaths worldwide annually.
BEIJING, Nov. 10, 2010 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, Inc.
OMAHA, Neb., Nov. 8, 2010 /PRNewswire-FirstCall/ -- Transgenomic, Inc.
PRINCETON, N.J., Oct.
Even though the cancer-treatment agent cetuximab is not considered effective treatment for KRAS (a gene)-mutated metastatic colorectal tumors, new research indicates that patients with colorectal cancer not responding to chemotherapy and a certain variation of this gene who were treated with cetuximab had longer overall and progression-free survival than patients with other KRAS-mutations.
Lung cancer patients who have already been treated with the EGFR inhibitors erlotinib or gefitinib seem to gain further benefits in terms of progression-free survival and tumor shrinkage when treated with the new drug afatinib.
Featured in the October edition of the Journal of Thoracic Oncology (JTO), data from The Tarceva Lung Cancer Survival Treatment (TRUST) confirms the safety and efficacy profile of erlotinib, a highly potent oral active, reversible inhibitor of epidermal growth factor receptor (EGFR) tyrosine-kinase (TK) activity in a large heterogeneous non-small cell lung cancer (NSCLC) population.
African-American patients with non-small cell lung cancer are just as likely to display an epidermal growth factor receptor (EGFR) mutation in tumors as Caucasians, which suggests they are as likely to benefit from targeted therapies such as erlotinib.
Molecularly targeted therapies can reduce tumors rapidly.
- An imitative word; an onomatopoetic word.